Research Analysts’ Recent Ratings Updates for Insulet (PODD)

A number of research firms have changed their ratings and price targets for Insulet (NASDAQ: PODD):

  • 5/9/2019 – Insulet was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 5/6/2019 – Insulet had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $110.00 price target on the stock, up previously from $100.00.
  • 5/6/2019 – Insulet was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $115.00 price target on the stock.
  • 5/1/2019 – Insulet was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/19/2019 – Insulet was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/11/2019 – Insulet was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 3/27/2019 – Insulet was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 3/19/2019 – Insulet was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.

Shares of NASDAQ:PODD traded down $4.19 during midday trading on Monday, hitting $98.99. The company had a trading volume of 68,726 shares, compared to its average volume of 762,571. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.37. The firm has a market capitalization of $6.26 billion, a price-to-earnings ratio of 1,979.80 and a beta of 1.50. Insulet Co. has a 12-month low of $70.80 and a 12-month high of $108.90.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, topping the consensus estimate of $0.02 by $0.05. The firm had revenue of $159.56 million during the quarter, compared to analyst estimates of $154.66 million. Insulet had a return on equity of 7.01% and a net margin of 2.37%. Insulet’s revenue was up 29.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.11) EPS. On average, equities research analysts expect that Insulet Co. will post 0.26 earnings per share for the current fiscal year.

In other Insulet news, EVP Aiman Abdel-Malek sold 27,349 shares of the stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $94.03, for a total value of $2,571,626.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael L. Levitz sold 1,350 shares of the stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $92.01, for a total value of $124,213.50. The disclosure for this sale can be found here. Insiders sold a total of 80,304 shares of company stock valued at $7,589,000 over the last 90 days. 3.50% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of PODD. Norges Bank purchased a new stake in Insulet in the 4th quarter worth $53,604,000. William Blair Investment Management LLC increased its stake in Insulet by 15.7% in the 1st quarter. William Blair Investment Management LLC now owns 2,144,988 shares of the medical instruments supplier’s stock worth $203,967,000 after buying an additional 290,790 shares in the last quarter. First Trust Advisors LP increased its stake in Insulet by 103.6% in the 4th quarter. First Trust Advisors LP now owns 458,028 shares of the medical instruments supplier’s stock worth $36,331,000 after buying an additional 233,075 shares in the last quarter. Frontier Capital Management Co. LLC increased its stake in Insulet by 12.3% in the 1st quarter. Frontier Capital Management Co. LLC now owns 1,958,736 shares of the medical instruments supplier’s stock worth $186,256,000 after buying an additional 214,033 shares in the last quarter. Finally, Standard Life Aberdeen plc purchased a new stake in Insulet in the 4th quarter worth $16,011,000.

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Read More: Different Options Trading Strategies

Receive News & Ratings for Insulet Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co and related companies with MarketBeat.com's FREE daily email newsletter.